Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019. Read the full article
EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of
Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch
Vaxess and GC Pharma will collaborate on Influenza vaccine smart release patch, in a deal which will give Vaxess exclusive
Kangpu Biopharmaceuticals doses first humans with KPG-818 for treating SLE and hematological malignancies
Kangpu Biopharmaceuticals has completed a first-in-human phase I single ascending dose (SAD) clinical study in the United States, testing KPG-818 for the treatment of SLE and hematological malignancies.
Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites
CHENGDU, China–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first
– Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation – OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi &
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis